ACS applied materials & interfaces

Nanomaterials (Basel, Switzerland)

international journal of nanomedicine

pakistan journal of pharmaceutical sciences

Theranostics

Chemical communications (Cambridge, England)

colloids and surfaces b, biointerfaces

Biomacromolecules

bioconjugate chemistry

Biochemical and biophysical research communications

journal of cancer research and therapeutics

drug development and industrial pharmacy

journal of materials chemistry b

Photodiagnosis and photodynamic therapy

Trends in cancer

the journal of infection

[1] Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells, and evaluation.

[2] Light-controllable systems based on TiO-ZIF-8 composites for targeted drug release: communicating with tumour cells.

[3] Ultrasensitive photoelectrochemical microRNA biosensor based on doxorubicin sensitized graphitic carbon nitride assisted by a target-activated enzyme-free DNA walker.

[4] SHORT COMMUNICATION-Anticancer activity of Ziziphus mauritiana roots against human breast cancer cell line.

[5] The synergistic cytotoxic effects of doxorubicin and extract on human breast cancer cell line T47-D.

[6] Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma.

[7] Galactose-based Thermosensitive Nanogels for Targeted Drug Delivery of Iodoazomycin Arabinofuranoside (IAZA) for Theranostic Management of Hypoxic Hepatocellular Carcinoma.

[8] Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.

[9] Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.

[10] Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

[11] Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study.

[12] mechanisms of antibiotic resistance

[13] novel polymyxin combination with antineoplastic mitotane improved the bacterial killing against polymyxin-resistant multidrug-resistant gram-negative pathogens

[14] pharmacological modulation of anti-tumor immunity induced by oncolytic viruses

[15] emerging therapies for childhood polycystic kidney disease

[16] a new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

[17] a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

[18] synergistic effect of haloduracin and chloramphenicol against clinically important gram-positive bacteria

[19] self-assembled albumin nanoparticles for combination therapy in prostate cancer

[20] Transferrin-Modified Nanoliposome Codelivery Strategies for Enhancing the Cancer Therapy

[21] Dual drug delivery system of RAPTA-C and paclitaxel based on fructose coated nanoparticles for metastatic cancer treatment.

[22] Drug independence and the curability of cancer by combination chemotherapy.

[23] Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges.

[24] In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

[25] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[26] Malaria parasite clearance from patients following artemisinin-based combination therapy in Côte d’Ivoire

[27] In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae

[28] In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital

[29] Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in Plasmodium falciparum malaria parasites from southeastern Côte-d'Ivoire by the time of Artemisinin-based Combination Therapy adoption in 2005

[30] Current perspectives on combination therapy in the management of hypertension

[31] Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

[32] Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: observations on efficacy and tolerability of monotherapy or combination therapy

[33] Azilsartan/chlorthalidone combination therapy for blood pressure control

[34] Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

[35] Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

[36] In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

[37] In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

[38] Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

[39] Malaria parasite clearance from patients following artemisinin-based combination therapy in Côte d’Ivoire

[40] In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae

[41] Successful Treatment of Sjögren’s Syndrome Presenting as a Condition Similar to Chronic Capillary Leak Syndrome Using Combination Therapy with High-Dose Intravenous Immunoglobulin and Glucocorticoid

[42] In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital

[43] Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in Plasmodium falciparum malaria parasites from southeastern Côte-d'Ivoire by the time of Artemisinin-based Combination Therapy adoption in 2005

[44] Current perspectives on combination therapy in the management of hypertension

[45] Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

[46] Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: observations on efficacy and tolerability of monotherapy or combination therapy

[47] Azilsartan/chlorthalidone combination therapy for blood pressure control

[48] Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

[49] Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

[50] Combination therapy targeting platelet activation and virus replication protects mice against lethal influenza pneumonia.

[51] Artemisinin-based combination therapy: knowledge and perceptions of patent medicine dealers in Owerri Metropolis, Imo State, Nigeria and implications for compliance with current malaria treatment protocol.

[52] Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study

[53] Photodynamic therapy using zinc phthalocyanine in low dose of diode laser combined with doxorubicin is a synergistic combination therapy for human SK-MEL-3 melanoma cells.

[54] Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.

[55] Self-assembled albumin nanoparticles for combination therapy in prostate cancer

[56] The effectiveness of combination therapy with 308-nm excimer laser in vitiligo in Han Chinese People.

[57] Utility of dermoscopy for evaluating the therapeutic efficacy of tacrolimus ointment plus 308-nm excimer laser combination therapy in localized vitiligo patients.

[58] The efficacy of 308 nm UV excimer light as monotherapy and combination therapy with topical khellin 4% and/or tacrolimus 0.1% in the treatment of vitiligo

[59] A successful helium-neon laser and topical tacrolimus combination therapy in one child with vitiligo

[60] The effectiveness of excimer laser on vitiligo treatment in comparison with a combination therapy of Excimer laser and tacrolimus in an Iranian population

[61] Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: A proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment

[62] Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania

[63] Exclusive plaque psoriasis of the lips: efficacy of combination therapy of topical tacrolimus, calcipotriol, and betamethasone dipropionate.

[64] Synthesis of doxorubicin and miRNA stimuli-sensitive conjugates for combination therapy

[65] Uniformly sized hollow microspheres loaded with polydopamine nanoparticles and doxorubicin for local chemo-photothermal combination therapy

[66] Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy

[67] Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.

[68] Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.

[69] Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.

[70] Combination Therapy and Opioids: Effectiveness of Transcranial Direct-Current Stimulation (tDCS) and Emotion Regulation Training in Reducing Current Drug Craving.

[71] Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes

[72] Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy

[73] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[74] Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

[75] Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

[76] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[77] Effective Combination Therapy Using Interferon-γ and Interleukin-2 for Disseminated Mycobacterium avium Complex Infection in a Pediatric Patient with AIDS

[78] Switch from Ritonavir to Indinavir in Combination Therapy for HIV-1—Infected Children

[79] Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

[80] Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

[81] Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

[82] Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

[83] sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

[84] step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy

[85] partial cranial cruciate ligament tears treated with stem cell and platelet rich plasma combination therapy in 36 dogs: a retrospective study

[86] inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for cancer: an overview of rationale, preclinical evidence, and initial clinical data

[87] pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report

[88] ace inhibitors – angiotensin ii receptor antagonists: a useful combination therapy for ischemic heart disease

[89] outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination

[90] long-lasting effects of anti-vegf/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review

[91] adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria: a systematic review and meta-analysis

[92] carfilzomib boosted combination therapy for relapsed multiple myeloma

[93] etanercept plus methotrexate: an effective combination therapy for recalcitrant pemphigus vulgaris

[94] combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

[95] a novel temperature-responsive micelle for enhancing combination therapy

[96] results of original herbal medicinal product use in combination therapy of pyelonephritis in children

[97] combination therapy with losartan and pioglitazone additively reduces renal oxidative and nitrative stress induced by chronic high fat, sucrose, and sodium intake

[98] glp-1 based combination therapy for obesity and diabetes

[99] case report: combination therapy with mesenchymal stem cells and granulocyte-colony stimulating factor in a case of spinal cord injury

[100] valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

[101] comparison of health service utilization for febrile children before and after introduction of malaria rapid diagnostic tests and artemisinin-based combination therapy in rural papua new guinea